Reduction on oxalate absorption in individuals

Abstract

In various implementations, an oxalate absorption blocking (OAB) composition may be administered to improve a health of an individual. The OAB composition may include calcium and / or magnesium. In some implementations, the OAB composition may include one or more carbonates, probiotics, vitamins and / or other minerals. A therapeutically effective amount of the OAB composition may be administered to reduce oxalate absorption from foods consumed by an individual. Reducing oxalate absorption from foods consumed by an individual may decrease pain, improve movement of joints, inhibit kidney stone formation, and / or otherwise improve an individual's health.20 24 21 31 74 22 A ug 2 02 4 A B S T R A C T 2 0 2 4 2 1 3 1 7 4 2 2 2 0 2 4 A u g

Claims

1. An oxalate absorption blocking composition comprising:800 mg to 2500 mg of calcium; and50 to 1500 mg of magnesium;wherein the oxalate absorption blocking composition is for oral administration, and wherein oral administration of the oxalate absorption blocking composition improves the health of an individual.

2. The oxalate absorption blocking composition for use according to claim 1 wherein the oxalate absorption blocking composition comprises one or more probiotics.

3. The oxalate absorption blocking composition for use according to claim 1 or claim 2, wherein the oxalate absorption blocking composition comprises Oxalobacter fonnigenes.

4. The oxalate absorption blocking composition for use according to any of the preceding claims wherein an atomic ratio of calcium to magnesium in the oxalate absorption blocking composition comprises approximately 1 to approximately 2 Calcium: to approximately 1 Magnesium.

5. The oxalate absorption blocking composition for use according to any of the preceding claims wherein the oxalate absorption blocking composition is administered at least twice a day.

6. The oxalate absorption blocking composition for use according to any of the preceding claim wherein the oxalate absorption blocking composition is administered proximate consumption of a meal.2024213174   22 Aug 20247.     The oxalate absorption blocking composition for use according to any of thepreceding claims wherein the oxalate absorption blocking composition comprises approximately 800 mg of Calcium to approximately 1000 mg of Calcium, and wherein the oxalate absorption blocking composition comprises approximately 200 mg of Magnesium to approximately 300 mg of Magnesium.

8. The oxalate absorption blocking composition for use according to any of thepreceding claims wherein the oxalate absorption blocking composition comprises an analgesic.

9. The oxalate absorption blocking composition for use according to any of thepreceding claims wherein the oxalate absorption blocking composition comprises approximately 800 mg of Calcium to approximately 1000 mg of Calcium.

10. The oxalate absorption blocking composition for use according to any of thepreceding claims wherein the oxalate absorption blocking composition comprises approximately 200 mg of Magnesium to approximately 300 mg of Magnesium.

11. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing symptoms of calcification of at least one of a spine or a shoulder.

12. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing fibromyalgia pain.

13. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing at least one of the frequency or size of kidney stones.2024213174   22 Aug 202414. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing at least one of gout flare ups or pain due to gout flare ups.

15. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing symptoms of a congenital disease related to hyper-absorption of oxalate by reducing oxalate absorption during consumption of meals.

16. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing symptoms of hyperoxaluria.

17. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing pain of rheumatoid arthritis.

18. A therapeutic method of orally administering the oxalate absorption blocking composition of any of the preceding claims for reducing symptoms of vulvodynia.

Images